INTS: Intensity Therapeutics, Inc. Stock

by  •  • Comments Off on INTS: Intensity Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 41.38
Enterprise Value ($M) 38.59
Book Value ($M) 2.78
Book Value / Share 0.18
Price / Book 14.89
NCAV ($M) 1.35
NCAV / Share 0.09
Price / NCAV 30.58

Profitability (mra)
Return on Invested Capital (ROIC) -5.56
Return on Assets (ROA) -0.97
Return on Equity (ROE) -1.02

Liquidity (mrq)
Quick Ratio 1.63
Current Ratio 1.63

Balance Sheet (mrq) ($M)
Current Assets 3.79
Assets 5.21
Liabilities 2.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
06-07 13G LFP Management, LLC 5.40
02-13 13G Bender Lewis H 16.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-27 1,683 4,477 37.59
2024-11-26 759 11,479 6.61
2024-11-25 7,414 28,457 26.05
2024-11-22 11,473 37,717 30.42

(click for more detail)

Similar Companies
INKT – MiNK Therapeutics, Inc. INM – InMed Pharmaceuticals Inc.
INMB – INmune Bio, Inc. IRD – Opus Genetics, Inc.
ITRM – Iterum Therapeutics plc


Financial data and stock pages provided by
Fintel.io